VOLANTE, Marco
 Distribuzione geografica
Continente #
NA - Nord America 13414
EU - Europa 9026
AS - Asia 4875
SA - Sud America 444
OC - Oceania 192
AF - Africa 151
Continente sconosciuto - Info sul continente non disponibili 23
Totale 28125
Nazione #
US - Stati Uniti d'America 13046
CN - Cina 2624
IT - Italia 2160
DE - Germania 927
IE - Irlanda 906
FR - Francia 850
SE - Svezia 751
UA - Ucraina 602
JP - Giappone 494
FI - Finlandia 481
KR - Corea 470
GB - Regno Unito 391
PL - Polonia 361
IN - India 327
AT - Austria 311
VN - Vietnam 293
CA - Canada 278
BR - Brasile 261
ES - Italia 250
TR - Turchia 203
NL - Olanda 177
AU - Australia 174
DK - Danimarca 128
GR - Grecia 121
RU - Federazione Russa 108
BE - Belgio 103
SN - Senegal 87
AR - Argentina 85
TW - Taiwan 80
MX - Messico 77
CH - Svizzera 73
HK - Hong Kong 60
PT - Portogallo 60
RO - Romania 57
IL - Israele 42
HU - Ungheria 38
CL - Cile 37
NO - Norvegia 35
CZ - Repubblica Ceca 34
SA - Arabia Saudita 34
TH - Thailandia 34
ID - Indonesia 33
PH - Filippine 32
CO - Colombia 31
MY - Malesia 27
SG - Singapore 26
UZ - Uzbekistan 25
RS - Serbia 24
HR - Croazia 23
DZ - Algeria 22
EU - Europa 22
NZ - Nuova Zelanda 18
SI - Slovenia 18
PK - Pakistan 17
EC - Ecuador 15
PE - Perù 12
ZA - Sudafrica 11
BY - Bielorussia 8
EG - Egitto 8
JO - Giordania 8
QA - Qatar 7
SK - Slovacchia (Repubblica Slovacca) 7
IQ - Iraq 6
IR - Iran 6
BG - Bulgaria 5
MA - Marocco 5
PR - Porto Rico 5
SD - Sudan 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
BA - Bosnia-Erzegovina 4
LT - Lituania 4
BD - Bangladesh 3
MK - Macedonia 3
MO - Macao, regione amministrativa speciale della Cina 3
MT - Malta 3
MU - Mauritius 3
OM - Oman 3
PA - Panama 3
SC - Seychelles 3
CU - Cuba 2
CY - Cipro 2
LB - Libano 2
RE - Reunion 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
ME - Montenegro 1
MM - Myanmar 1
MW - Malawi 1
NI - Nicaragua 1
NP - Nepal 1
RW - Ruanda 1
Totale 28121
Città #
Chandler 1465
Beijing 1389
Houston 1121
Fairfield 1088
Dublin 893
Ann Arbor 701
Redwood City 659
Torino 577
Wilmington 569
Woodbridge 561
Ashburn 483
Seattle 457
Villeurbanne 397
Jacksonville 375
Cambridge 362
Pisa 328
Medford 300
Princeton 299
Vienna 292
Dearborn 289
Nyköping 277
Warsaw 259
Dong Ket 171
Shanghai 148
Boston 147
Fremont 135
Tokyo 131
Milan 115
Nanjing 103
Guangzhou 99
Hangzhou 95
Boardman 93
Würzburg 86
San Diego 82
Seoul 68
Toronto 66
Chicago 64
Chengdu 63
Munich 61
New York 56
São Paulo 55
Norwalk 54
Düsseldorf 51
Taipei 51
Verona 50
Hefei 47
Phoenix 46
Falls Church 45
Paris 45
Zhengzhou 44
Brussels 43
Shenyang 43
Bologna 42
Athens 39
Pittsburgh 39
Silver Spring 39
Madrid 38
Buenos Aires 37
New Delhi 36
Rome 36
Bethesda 35
Canberra 35
Wuhan 35
Brescia 34
Istanbul 34
Kunming 33
Mountain View 33
Santiago 32
Central District 30
Florence 30
Ankara 28
Lexington 28
London 28
Turin 28
Jinan 27
Rochester 27
Amsterdam 26
Changsha 26
Hebei 26
Padova 25
Piemonte 25
Gurgaon 24
Montréal 24
Birmingham 23
Dallas 23
Barcelona 22
Lyon 22
Mexico 22
Moscow 22
Napoli 22
Oslo 22
Calgary 20
Duncan 20
Munro 20
Nanchang 20
Xian 20
Changchun 19
Copenhagen 19
Durham 19
Los Angeles 19
Totale 16831
Nome #
The weiss score and beyond--histopathology for adrenocortical carcinoma. 1301
Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology 800
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. 760
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma 538
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 529
Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: Targeted Next Generation Sequencing Suggests a Monoclonal Origin of the Two Components 488
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. 482
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. 425
IMPACT OF PREGNANCY ON PROGNOSIS OF DIFFERENTIATED THYROID CANCER: CLINICAL AND MOLECULAR FEATURES. 372
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 370
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. 368
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. 351
Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. 350
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart 318
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. 317
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact 303
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones 300
Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. 293
Functional Role and Prognostic Significance of CD157 in Ovarian Carcinoma 271
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 269
Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia 265
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 262
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 261
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer 260
MITOTANE LEVELS PREDICT THE OUTCOME OF PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION. 260
An exploration of pathways involved in lung carcinoid progression using gene expression profiling 258
Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells 245
Pathology of the Adrenal Cortex: a Reappraisal of the Past 25 Years Focusing on Adrenal Cortical Tumors. 241
Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. 238
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. 237
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 236
Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours 219
An international Ki67 reproducibility study in adrenal cortical Carcinoma 219
Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. 214
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 214
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates 209
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 204
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 203
MEN1 Gene Mutation and Reduced Expression Are Associated with Poor Prognosis in Pulmonary Carcinoids 202
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. 198
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: A case report and review of the literature 179
Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis 179
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma 179
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC 177
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 170
H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features data from a multi-institutional series 164
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 162
Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis 161
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 158
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma 156
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. 156
mTORC1 Complex is Significantly Over-Activated in SDHX-Mutated Paragangliomas 153
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 149
Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. 147
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 145
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 142
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors 142
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 141
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 137
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 137
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. 137
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study 125
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. 123
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T) 121
Tissue arrays as fiducial markers for section alignment in 3-D reconstruction technology 120
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid 115
Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures 113
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma 110
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. 110
Thymidylate synthase expression in large cell carcinoma ofthe lung 109
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. 109
RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β-cells and human pancreatic islets but exert opposite effects on insulin secretion. 103
Biological role and clinical significance of CD157 in epithelial ovarian cancer 102
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS 102
Mechanical phenotyping of cells and extracellular matrix as grade and stage markers of lung tumor tissues 102
Biological role, clinical significance and potential therapeutic applications of CD157 in ovarian cancer 99
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells 98
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 98
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 97
Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation 97
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine 94
Absence of gene mutations in a case of concomitant presence of carcinoid of the ampulla of vater pheochromocytoma and Von Recklinghausen disease 93
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung 92
Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies. 90
Valutazione prospettica di pazienti operati radicalmente per carcinoma corticosurrenalico in trattamento con mitotane adiuvante: correlazioni tra indici di massa corporea, livelli di mitotanemia ed efficacia. 89
Extensive DNA fragmentation in oxyphilic cell lesions of the thyroid. 88
CD157: A New Prognostic and/or Predictive Marker in Ovarian Cancer? A Retrospective Study 88
Cytology of Primary Salivary Gland-Type Tumors of the Lower Respiratory Tract: Report of 15 Cases and Review of the Literature 88
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network 86
Adjuvant mitotane treatment: a prospective experience at the San luigi Hospital, University of Turin, Italy, USA, 2008 86
Clinical and biological significance of CD157 in malignant pleural mesothelioma 86
DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma 86
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma 86
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 85
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 84
Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats 83
Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study 82
The San Luigi hospital experience with adjuvant mitotane treatment in patients with adrenocortical cancer following radical resection 81
CD157 is a novel prognostic marker of malignant pleural mesothelioma involved in the control of tumor aggressiveness 81
Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia 81
Totale 20903
Categoria #
all - tutte 42046
article - articoli 0
book - libri 0
conference - conferenze 3346
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45392


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182787 0000 00 0637 1049678201222
2018/20194053 275193263237 239232 237441 242392867435
2019/20205919 350348382663 487922 660488 548469329273
2020/20214472 365266387258 375395 445255 400408378540
2021/20224318 262297252373 267235 302296 190300796748
2022/20233842 549448175511 4701226 4585 0000
Totale 29186